Figure 5

Salidroside suppresses tumor growth in syngeneic tumor model. (A) Body weight of mice during the treatment period. (B) Tumor volume of mice during the treatment period. *p < 0.05. (C) Tumor weight (left panel) and representative photos of tumor dissected from mice (right panel). *p < 0.05, ***p < 0.005, vs. control group. n=4. Sal-S: salidroside 4 mg/kg. Sal-H: salidroside 8 mg/kg. (D) HE and IHC staining of Ki-67, miTF, and mTOR in tumor tissues. Representative melanoma sections from mice of each group are presented in the left panels. Relative positive rates are shown in the right panels. Data are presented as mean ± SD of four mice. **p < 0.01, ***p < 0.005, ****p < 0.001. vs. control group, scale bar = 100 μm. (E) The expression of Ki-67 and mTOR were detected by IHC assay in the tumor issues of mice (n=4). Data were presented as the mean ± SD, scale bar = 200 μm, **p < 0.01, ****p < 0.001. HE, hematoxylin and eosin; IHC, immunohistochemistry; SD, standard deviation.